1-10 of 10
Sylvia Herter, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies

Sylvia Herter, PhD, Johannes Sam, PhD, Claudia Ferrara Koller, PhD, Sarah Diggelmann, Esther Bommer, Anne Schönle, Christina Claus, PhD, Marina Bacac, PhD, Christian Klein, PhD, Pablo Umana, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40.
https://doi.org/10.1182/blood-2020-134782
Published: 2020
Journal Articles

Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma

Martin Hutchings, MD PhD, Fritz C. Offner, MD PhD, Francesc Bosch, MD PhD, Giuseppe Gritti, MD PhD, Carmelo Carlo-Stella, MD, Harriet Walter, William Townsend, MRCP,MDFRCPath, Franck Morschhauser, MD PhD, Guillaume Cartron, MD PhD, Hervé Ghesquieres, MD PhD, Sophie de Guibert, MD, Sylvia Herter, PhD, Koorosh Korfi, PhD, Veronica Craine, Sarah Louise Mycroft, Matt Whayman, Claudia Mueller, Natalie Dimier, PhD, Tom Moore, MBChB, Sara Belli, Martin Kornacker, MD, Katharina Lechner, Michael Dickinson, DMed Sci
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-136571
Published: 2020
Journal Articles

CD20 Tcb (RG6026), a Novel "2:1" T Cell Bispecific Antibody for the Treatment of B Cell Malignancies

Marina Bacac, PhD, Pablo Umaña, PhD, Sylvia Herter, PhD, Sara Colombetti, PhD, Johannes Sam, PhD, Marine Le Clech, Anne Freimoser-Grundschober, PhD, Marine Richard, Valeria Nicolini, PhD, Christian Gerdes, PhD, Laurent Lariviere, PhD, Christiane Neumann, PhD, Christian Klein, PhD
Journal: Blood
Blood (2016) 128 (22): 1836.
https://doi.org/10.1182/blood.V128.22.1836.1836
Published: 2016
Journal Articles

Obinutuzumab (GA101) Is Less Prone to Antagonism of Immune Effector Function By Ibrutinib Than Rituximab in Vitro and in Vivo

Sylvia Herter, PhD, Idit Sagiv-Barfi, PhD, Cariad Chester, Mohith Sadaram, BS, Jonathan Hebb, MD, Debra K Czerwinski, Narendiran Rajasekaran, PhDMSc, Marina Bacac, PhD, Pablo Umana, PhD, Ron Levy, MD, Christian Klein, PhD, Holbrook E Kohrt, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1765.
https://doi.org/10.1182/blood.V124.21.1765.1765
Published: 2014
Journal Articles

Combination of the Glycoengineered Type II CD20 Antibody Obinutuzumab (GA101) and the MDM2 Selective Antagonist RG7388 Results in Superior Anti-Tumor Activity

Frank Herting, PhD, Sylvia Herter, PhD, Thomas Friess, PhD, Christian Lehmann, PhD, Marina Bacac, PhD, Markus Dangl, PhD, Christian Klein, PhD
Journal: Blood
Blood (2014) 124 (21): 1780.
https://doi.org/10.1182/blood.V124.21.1780.1780
Published: 2014
Journal Articles

The PI3K Delta Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function and B Cell Depletion Mediated By Obinutuzumab (GA101) and Rituximab

Sylvia Herter, PhD, Adam Palazzo, Marina Bacac, PhD, Laura Grosmaire, MS, Christian Frey, PhD, Stefan Pflanz, PhD, Jia Liu, PhD, Stacey Tannheimer, PhD, Pablo Umana, PhD, Christian Klein, PhD, Christophe Queva, PhD
Journal: Blood
Blood (2014) 124 (21): 3342.
https://doi.org/10.1182/blood.V124.21.3342.3342
Published: 2014
Journal Articles

Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101) and The novel Bcl-2 selective Inhibitor GDC-0199 Results in superior In Vitro and In Vivo Anti-tumor activity in models Of B-Cell Malignancies

Deepak Sampath, PhD, Sylvia Herter, PhD, Frank Herting, Ellen Ingalla, Michelle Nannini, Marina Bacac, Wayne J. Fairbrother, PhD, Christian Klein, PhD
Journal: Blood
Blood (2013) 122 (21): 4412.
https://doi.org/10.1182/blood.V122.21.4412.4412
Published: 2013
Journal Articles

Novel Tumor-Targeted, Engineered IL-2 Variant (IL2v)-Based Immunocytokines For Immunotherapy Of Cancer

Christian Klein, PhD, Inja Waldhauer, PhD, Valeria Nicolini, PhD, Claire Dunn, PhD, Anne Freimoser-Grundschober, PhD, Gerrits Danny, PhD, Otto Boerman, PhD, Tapan Nayak, PhD, Sylvia Herter, PhD, Erwin Van Puijenbroek, Oliver Ast, PhD, Thomas Hofer, PhD, Ralf Hosse, Sabine Lang, Sebastian Neumann, Hubert Kettenberger, Markus Neubauer, Ingo Gorr, Dietrich Tuerck, Stefan Evers, Christian Gerdes, Victor Levitsky, Marina Bacac, Ekkehard Moessner, Pablo Umana, PhD
Journal: Blood
Blood (2013) 122 (21): 2278.
https://doi.org/10.1182/blood.V122.21.2278.2278
Published: 2013
Journal Articles

Obinutuzumab (GA101) More Potently Engages Phagocytic-Lineage Cells Resulting In Enhanced Monocyte and Macrophage Activity When Compared To Rituximab and Ofatumumab

Sylvia Herter, PhD, Christian Klein, PhD, Pablo Umana, PhD, Marina Bacac
Journal: Blood
Blood (2013) 122 (21): 5136.
https://doi.org/10.1182/blood.V122.21.5136.5136
Published: 2013
Journal Articles

GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Exhibits Superior Anti-Tumor Efficacy and Superior Tissue B Cell Depletion In Vivo.

Pablo Umana, PhD, Moessner Ekkehard, PhD, Bruenker Peter, PhD, Klingner Gabriele, Puentener Ursula, PhD, Tobias Suter, PhD, Roger Grau, PhD, Carla Schmidt, PhD, Sylvia Herter, PhD, Christian Gerdes, PhD, Adam Nopora, PhD, Monika Patre, PhD, Samuel Moser, PhD, Peter Sondermann, PhD, Luise Wheat, PhD, Martin J.S. Dyer, PhD, Sibrand Poppema, PhD, Sabine Bauer, PhD, Manfred Kubbies, PhD, Pamela Strein, PhD, Georg Fertig, PhD, Thomas Friess, PhD, Karim Dabbagh, PhD, Joe DalPorto, PhD, Christian Klein, PhD
Journal: Blood
Blood (2007) 110 (11): 2348.
https://doi.org/10.1182/blood.V110.11.2348.2348
Published: 2007